Healthcare entity
Every one of those 1 sits in a single category, health-it. Insilico Medicine is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 6 runs above the beat's 5.8 for that window.
Last mentioned: Mar 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, health-it. Insilico Medicine is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 6 runs above the beat's 5.8 for that window. Source depth averages 3 original sources per story, versus 3.6 across the same-window beat baseline. ISM4808 appears in 1 tracked Healthcare story from March 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ISM4808. Shared-story counts are live from our verified record — not editorial picks.
Phase I Milestone
First human subject enrolled and dosed in the Phase I clinical trial.
AI Discovery
Insilico Medicine identifies ISM4808 using its Pharma.AI platform.
Out-Licensing
TaiGen Biotechnology secures rights for the clinical development of the candidate.
Insilico Medicine and TaiGen have successfully enrolled and dosed the first human subject in a Phase I clinical trial for ISM4808, a novel drug candidate for Chronic Kidney Disease (CKD) anemia. The milestone validates the clinical transition of an AI-discovered molecule under a strategic out-licensing agreement.
Source: finanznachrichten.de · manilatimes.net
ISM4808 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
